ACHV Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (ACHV) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.4% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States.
Sector
Healthcare
Industry
Drug Manufacturers/Other